Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab PK Comparability Study (IV/SC/OBDS)
NCT05274100Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2020
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of risankizumab in plaque psoriasis, psoriatic arthritis (PsA) and Crohn's disease (5 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants Experiencing Adverse Events up to 140 days, Maximum Observed Serum Concentration up to 113 days and 5 more. Started Sep 2020; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)Crohn's disease
Beyond the preview
Go deeper on NCT05274100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05274100.